Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin A Nephropathy
IgAN

Interventions

DRUG: Ravulizumab
DRUG: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.